3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
45
Lymphoma, Mantle-Cell
22
Waldenstrom Macroglobulinemia
12
Lymphoma, Non-Hodgkin
10
Lymphoma, Large B-Cell, Diffuse
10
Lymphoma, Follicular
10
Lymphoma, B-Cell
10
Leukemia
10
Recurrence
7
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma
6
Neoplasms
4
Hodgkin Disease
4
Leukemia, Prolymphocytic
3
Leukemia, Lymphoid
3
Leukemia, B-Cell
3
Chromosome 17 deletion
3
Burkitt Lymphoma
3
Bronchiolitis Obliterans Syndrome
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Leukemia, Myeloid, Acute
2
Leukemia, Hairy Cell
2
Hematologic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Smoldering Multiple Myeloma
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Plasma Cell
1
Neoplasm, Residual
1
Interventions
Rituximab
8
Cyclophosphamide
8
Peripheral Blood Stem Cell Transplantation
7
Methotrexate
7
fludarabine phosphate
6
Whole-Body Irradiation
5
Tacrolimus
5
Mycophenolic Acid
5
Dexamethasone
5
Cyclosporine
5
Cytarabine
4
Transplantation
3
Radiotherapy
3
Filgrastim
3
Busulfan
3
pegfilgrastim
2
merphos
2
etoposide phosphate
2
Methylprednisolone
2
Lenalidomide
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Carboplatin
2
Calcium Dobesilate
2
Antilymphocyte Serum
2
zanubrutinib
1
sodium thiosulfate
1
sargramostim
1
oblimersen
1
ibrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Intraocular Lymphoma
×
ibrutinib
×
Clear all
NCT02542514
2022-04-14
iLOC
The Lymphoma Academic Research Organisation
Phase 2
Completed
52 enrolled